The study of the efficacy of a second line Luteinizing hormone-releasing hormone agonist after prostate cancer biochemical recurrence
Not Applicable
- Conditions
- Patients with prostate cancer who received luteinizing hormone-releasing hormone (LH-RH) agonist, had biochemical progression
- Registration Number
- JPRN-UMIN000011255
- Lead Sponsor
- Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1. Serum teststerone level above 0.5ng/ml 2. Patient with clinical symptom, bone pain or urinary retention at PSA failure 3. Patient with the treatment history, who was administered both goserelin and leuprolide 4. Patient administered anti-androgen drug as CAB 5. Administeration of estrogen 6. Sytemic administeration of corticosteroid 7. Patient received chemotherapy 8. Patient with severe diabetes 9. Patients with severe psychosis 10. Patients with double cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percent prostate specific antigen change after switching luteinizing hormone-releasing hormone agonist therapy at 3 and 6 months
- Secondary Outcome Measures
Name Time Method